MediGene and Pharmanova Sign Agreement for the Commercialization of Veregen in Southeastern Europe
MediGene AG has signed an exclusive license and supply agreement with Pharmanova d.o.o. for the supply and commercialization of Veregen® ointment in Serbia, Bosnia and Herzegovina, Montenegro, Macedonia, Croatia, Slovenia, and Albania, for the treatment of genital warts. MediGene is entitled to successive payments, due upon the achievement of set regulatory and sales milestones, and will receive double-digit royalties on sales of Veregen®. Further financial details of the agreement were not disclosed. Pharmanova will be responsible for the drug approval procedure in the above mentioned countries (except Slovenia).
MediGene has already entered into several marketing partnerships for Veregen®, e.g. with Nycomed, Inc. for the USA, with Abbott for Germany, Austria, and Switzerland, with Laboratoires Expanscience for France, with Meditrina Pharmaceuticals for Greece, Cyprus, Romania and Bulgaria, and with a number of other partners across Europe, America, and Asia. MediGene is planning to continue this global licensing strategy.
Other news from the department business & finance
